Literature DB >> 23382624

Obesity and cholangiocarcinoma.

Mansour A Parsi1.   

Abstract

It is estimated that about half of the population in developed countries are either overweight or obese. In some developing nations obesity rates have increased to surpass those seen in Western countries. This rate increase in obesity has many implications as obesity has been associated with numerous negative health effects including increased risks of hypertension, diabetes, cardiovascular disease, stroke, liver disease, apnea, and some cancer types. Obesity is now considered to be one of the major public health concerns facing the society. Cholangiocarcinomas (bile duct cancers) are malignant tumors arising from cholangiocytes inside or outside of the liver. Although cholangiocarcinomas are relatively rare, they are highly lethal. The low survival rate associated with cholangiocarcinoma is due to the advanced stage of the disease at the time of diagnosis. Prevention is therefore especially important in this cancer type. Some data suggest that the incidence of cholangiocarcinoma in the western world is on the rise. Increasing rate of obesity may be one of the factors responsible for this increase. Determining whether obesity is a risk factor for cholangiocarcinoma has significant clinical and societal implications as obesity is both prevalent and modifiable. This paper seeks to provide a summary of the current knowledge linking obesity and cholangiocarcinoma, and encourage further research on this topic.

Entities:  

Keywords:  Bile ducts; Cancer; Cholangiocarcinoma; Epidemiology; Obesity

Mesh:

Year:  2013        PMID: 23382624      PMCID: PMC3558569          DOI: 10.3748/wjg.v19.i4.457

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  75 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Tumor necrosis factor alpha promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2.

Authors:  Yoko Tanimura; Toshio Kokuryo; Nobuyuki Tsunoda; Yukiko Yamazaki; Koji Oda; Yuji Nimura; Naing Naing Mon; Pengyu Huang; Yasuni Nakanuma; Min-Fu Chen; Yi-Yin Jan; Ta-Sen Yeh; Cheng-Taug Chiu; Ling-Ling Hsieh; Michinari Hamaguchi
Journal:  Cancer Lett       Date:  2005-03-10       Impact factor: 8.679

3.  Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma.

Authors:  Shusaku Ohira; Motoko Sasaki; Kenichi Harada; Yasunori Sato; Yoh Zen; Kumiko Isse; Kazuto Kozaka; Akira Ishikawa; Koji Oda; Yuji Nimura; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  Banking on the future: biobanking for "omics" approaches to biomarker discovery for Opisthorchis-induced cholangiocarcinoma in Thailand.

Authors:  Jason Mulvenna; Ponlapat Yonglitthipagon; Banchob Sripa; Paul J Brindley; Alex Loukas; Jeffrey M Bethony
Journal:  Parasitol Int       Date:  2011-08-09       Impact factor: 2.230

Review 5.  Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Eric Masuyer; Maria-Paula Curado; Veronique Bouvard; Yue-Yi Fang; Surapon Wiangnon; Banchob Sripa; Sung-Tae Hong
Journal:  Cancer Sci       Date:  2009-12-04       Impact factor: 6.716

6.  Serum and bile interleukin 6 after percutaneous transhepatic cholangio-drainage.

Authors:  T Akiyama; T Hasegawa; T Sejima; H Sahara; K Seto; H Saito; S Takashima
Journal:  Hepatogastroenterology       Date:  1998 May-Jun

Review 7.  Cholangiocarcinoma: lessons from Thailand.

Authors:  Banchob Sripa; Chawalit Pairojkul
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

8.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

9.  Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?

Authors:  Shahid A Khan; Shireen Emadossadaty; Nimzing G Ladep; Howard C Thomas; Paul Elliott; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

10.  The antecedents of biliary cancer: a primary care case-control study in the United Kingdom.

Authors:  M J Grainge; J West; M Solaymani-Dodaran; G P Aithal; T R Card
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

View more
  6 in total

Review 1.  Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.

Authors:  Letiția Adela Maria Streba; Cristin Constantin Vere; Ion Rogoveanu; Costin Teodor Streba
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

2.  Adiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort.

Authors:  Baiyu Yang; Jessica L Petrick; Scott P Kelly; Barry I Graubard; Neal D Freedman; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2017-04-26       Impact factor: 7.396

3.  Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.

Authors:  Chaitanya R Churi; Rachna Shroff; Ying Wang; Asif Rashid; HyunSeon C Kang; Jacqueline Weatherly; Mingxin Zuo; Ralph Zinner; David Hong; Funda Meric-Bernstam; Filip Janku; Christopher H Crane; Lopa Mishra; Jean-Nicholas Vauthey; Robert A Wolff; Gordon Mills; Milind Javle
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

Review 4.  Targeted Therapy in Biliary Tract Cancers.

Authors:  Amartej Merla; Kenneth G Liu; Lakshmi Rajdev
Journal:  Curr Treat Options Oncol       Date:  2015-10

5.  Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study.

Authors:  Jeffrey S Chang; Chia-Rung Tsai; Li-Tzong Chen
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

Review 6.  Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development.

Authors:  Ludovica Ceci; Tianhao Zhou; Ilaria Lenci; Vik Meadows; Lindsey Kennedy; Ping Li; Burcin Ekser; Martina Milana; Wenjun Zhang; Chaodong Wu; Keisaku Sato; Sanjukta Chakraborty; Shannon S Glaser; Heather Francis; Gianfranco Alpini; Leonardo Baiocchi
Journal:  Cancers (Basel)       Date:  2022-03-11       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.